<DOC>
	<DOCNO>NCT01935089</DOCNO>
	<brief_summary>We propose test primary hypothesis treatment Peg-IFN-α-2b result decrease integrate HIV DNA peripheral blood tissue chronically HIV-infected immune-reconstituted individual ( see section 3.1 ) prospective , interventional , 1-arm , open label clinical trial . To end , propose enroll 25 HIV-1-infected subject ( please refer power calculation section 10.1 ) currently stably suppress ( &gt; 1y VL &lt; 50 copies/ml ) ART CD4 count &gt; 450 cells/µl . We hypothesize 20 week treatment Peg-IFN-alpha-2b , presence HIV reactivation ( i.e . : ART interruption ) , result activation intrinsic and/or immune-mediated anti-HIV mechanism result decrease level viral reservoir chronically HIV-infected , immune-reconstituted individual .</brief_summary>
	<brief_title>Pilot Peg-Interferon-a2b Decreasing Viral DNA HIV</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1865 year age Body weight 125 299 lb Confirmed diagnosis HIV1 infection western blot document HIV1 viral load Currently receive ART ART &gt; 1 year VL &lt; 50 copies/ml ≥ 1 year , least 2 measurement previous year , 1 viral `` blip '' VL &lt; 400 copies/ml allow HIV viral load &lt; 50 copies/ml screening . CD4 &gt; 450 cells/µL screening . A negative ECG &gt; 45yrs men/ &gt; 55yrs woman year age year age two add risk factor coronary artery disease [ smoking , hypertension ( BP &gt; 140/90 antihypertensive medication ) , low HDL ( &lt; 40 mg/dL ) , family history premature CHD ( &lt; 55 yr males/ &lt; 65 female ) ] Framingham score &gt; 15 % ( men ) 10 % ( woman ) ) Confirmed clinical history develop resistance ART regimens result treatment change Receiving didanosine part participant 's ART regimen time screen Ongoing treatment Isoniazide , pyrazinamide , Rifabutin , Rifampicin , Diadenosine Ganciclovir , Valgancyclovir , Oxymetholone , Thalidomide Theophylline . Use investigational drug within 30 day prior screen History current use immunomodulatory therapy 2 week 6 month prior enrollment , include , limited : IFNalpha gamma ( recombinant pegylated ) , systemic corticosteroid ( nasal pulmonary steroid allow ; systemic cancer chemotherapy/irradiation ; cyclosporin ; tacrolimus ( FK506 ) ; OKT3 ; Interleukin , include IL2 ; cyclophosphamide ; methotrexate ; IVIG ( gamma globulin ) ; G/MCSF ; hydroxyurea ; thalidomide ; pentoxifylline ; thymopentin ; thymosin ; dithiocarbonate ; polyribonucleotide . History adverse allergic reaction type1 interferon ( e.g . IFNalpha2a , IFNα2b , IFNbeta ) History severe depression , ongoing moderate depression determine PHQ9 screen Type I diabetes mellitus , type II diabetes mellitus control oral agent and/or insulin . Prior diagnosis multiple sclerosis neurodegenerative disorder Significant coexist lab abnormality include : 1 . Anemia ( Hgb &lt; 9.1 mg/dl men , &lt; 8.9 mg/dl woman ) 2 . WBC &lt; 2000 cells/µl 3 . Absolute neutrophil count ( ANC ) &lt; 1200 cells/ µl 4 . Platelet count &lt; 60,000 cells/ µl 5 . Liver disease ( AST/ALT &gt; 2.5x , Total Bilirubin &gt; 1.5x upper limit norm ( ULN ) , Total Bilirubin &gt; 3x ULN receive indinavir OR Atazanavir ) 6 . Renal disease ( creatinine &gt; 2x upper normal limit creatinine clearance &lt; 60mg/dl ( CrockoffGault ) Chronic HCV infection ( HCV viremia ) , HBV Ag positive and/ HBV viremia ( Notice : subject prior HCV infection document sustained virologic response treatment finish &gt; 1 year prior screen eligible enrollment ) . Liver cirrhosis hepatic decompensation Child Pugh score &gt; 6 History major organ transplantation exist functional graft . Evidence OI active infectious disease active malignancy Active Autoimmune disease , include autoimmune hepatitis History retinopathy clinically significant ophthalmologic disease eye exam perform within 6 month prior initiation IFN Pregnancy , actively attempt become pregnant , breastfeed Body weight 125 lbs 300 lb Other condition , active drug/alcohol abuse dependence would interfere study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Interferon alpha</keyword>
	<keyword>Integrated DNA</keyword>
	<keyword>Latent reservoir</keyword>
</DOC>